![]() |
|
![]() | ||
470 Evergreen Woods,
Bangor, Maine 04401
Phone: 207.942.2898 Fax: 207.941.8818 |
![]() |
PENDING INVESTIGATIONS and CASES Please contact our office if you have questions or want more information about pending investigations and cases.
Accutane → More about Accutane side effects Investigations are assessing the side effects of Accutane. Some of the side effects now being investigated are birth defects, suicide, Crohn’s disease, ulcerative colitis, bone and muscle injuries, Irritable Bowel Syndrome (IBS), liver damage, kidney disease, immune diseases, pancreatitis, hearing and vision loss, lupus and thyroid disorders. Ancure Endograft Recall → More about Ancure Endograft side effects Guidant Corporation has pulled the Ancure AAA Endograft device from the market after the company pleaded guilty to ten felonies associated with the device. Bextra → More about Bextra side effects Bextra has been shown to increase the risk of heart attacks and strokes associated with blood-clotting problems. The drug has been linked to Stevens Johnson Syndrome, an extreme allergic reaction to skin. Additional information on Bextra side effects Fosamax® → More about Fosamax® side effects This popular drug has been linked to the development of osteonecrosis of the jaw, or ONJ, a rare and serious condition that causes breakdown and death of the jaw bone. Ortho Evra® Birth Control Patch → More about Ortho Evra® side effects FDA records show patch users between the ages of 17 and 30 have suffered fatal heart attacks, blood clots and possible strokes. Prempro & Premarin HRT → More about Prempro side effects The popular hormone replacement therapy drugs Prempro and Premarin have been linked to lobular and ductal breast cancer, ovarian cancer, heart disease and stroke. Vioxx → More about Vioxx side effects In 2004, Merck Pharmaceuticals announced a voluntarily withdrawal of Vioxx from the market due to safety concerns. Studies had shown that Vioxx increased the risk of blood clots linked to strokes and heart attacks. Since 1999, 91 million prescriptions for Vioxx were written in the United States. In April 2002, the Food and Drug Administration (FDA) implemented Vioxx labeling changes after Merck submitted a safety study finding an increased risk of serious cardiovascular events, including heart attacks and strokes, in patients taking Vioxx compared to naproxen. A recent FDA study also found patients taking Vioxx faced a 50% greater risk of heart attacks and sudden cardiac death compared to those taking Celebrex. Other studies have also suggested the increased risk of cardiovascular events for patients using Vioxx. | |